TG Therapeutics: Why I'm Staying Long After The Q2 Selloff (NASDAQ:TGTX)

seekingalpha.com · 2026-08-03

TG Therapeutics, Inc. stays a Buy as BRIUMVI revenue jumps and 2026 guidance rises; subcutaneous Phase 3 is a catalyst. Click for this TGTX stock update.

Read the full story at seekingalpha.com →